Overview
Psychiatric medicine is now advancing from solely descriptive disease classification toward a biologically based taxonomy. This evolution is more protracted than for other branches of medicine given the complexity of the neural systems that underlie human mental function and the challenge of characterizing psychiatric phenotypes objectively and quantitatively. The ultimate goal of this exercise is to describe the mechanistic and phenotypic variability within and across traditional diagnostic boundaries in a manner that identifies risk and resilience factors, provides early detection, predicts clinical outcomes, and specifies targets for trajectory-altering therapeutics and prevention.
The DSM-III classification of the American Psychiatric Association has been helpful in this regard by standardizing the assessment of symptoms and syndromes in a multifactorial, biopsychosocial context. Additionally, the Research Domain Criteria of the National Institute of Mental Health emphasize moving toward studying intermediate phenotypes (eg, endophenotypes and vide infra). While helpful when implemented as suggested in the Research Domain Criteria, the characterization of these endophenotypes may be too limited and not fully integrative. The heterogeneity within traditional diagnoses and the comorbidity among diagnoses require a more multidimensional molecular approach.
The Existing Evidence
Such an approach has been developed in network medicine. 1 Network medicine combines systems biology and network science approaches in analyzing genomic and pathophenotypic data, moving from correlations to pathway-based causations of diseases. Advances in biomedical "omics" and informatics have facilitated a move from traditional organ system-based categorizations toward the adoption of a systems model of the pathobiologies of specific diseases. Analyzing these large molecular genomic data sets has transitioned from seeking simple associations between a molecule or genetic variant with a disease phenotype to creating a complex network of relationships among these molecules based on their physical interactions or mechanistic ties that offers greater insight into causations and consequences. A data-driven molecular interactome emerges that is composed of subsets of overlapping biologically and clinically relevant network disease modules, or subnetworks of locally interacting pathways underlying a given disease. 2 Identifying these modules enables a mapping of the underlying mechanistic pathways that drive pathobiology and may cross conventional disease boundaries. 2 It also allows for the identification of the integrated dynamics of physiological adaptations, 3 environmental effects, and drug effects. Essentially, network medicine represents the next stage of precision medicine and illuminates the functional interactions among the multifactorial elements of human disease expressions and treatments. The value of this approach was first demonstrated in internal medicine. For example, the common endophenotypes governing all human diseases comprise unique modules within the interactome-the inflammasome, the thrombosome, and the fibrosome-that overlap with each other as a consequence of common pathways and with most disease modules, or clusters of interacting molecular mediators of a disease that are discretely localized within the interactome. 4 The exposome (environmental exposures), social determinants of health, 5 the microbiome, patient behavior, patientgenerated or passive sensor data, and electronic medical record data can also be incorporated for a more complete understanding of a disease phenotype, nuanced subtypes of which will be essential for developing an effective precision medicine platform. 6 Disease-disease relationships can be more fully understood and predicted in this context based on the degree of the genetic or interactome module overlap. Asthma and celiac disease, for instance, overlap in disease space in the immune network for IgA production. 2 In psychiatry, the search for sensitive and specific biomarkers or high-effect genes has been difficult because of polygenic, epigenetic, and psychobiological complexities. In this case, disease network approaches are better for developing "profiles of profiles" or "networks of networks" that may define clinically relevant distinctions and overlaps. Progress has been made in combining several measures, such as systems-level functional brain imaging (that identifies circuits and nodes of abnormal activity or connectivity, even in the absence of macroscopic "neurologic" lesions) and endocrinological, neuropsychological, behavioral, symptom-based, and functional genetic variant data. There has also been initial work done to incorporate metabolomics and lipidomics into these increasingly complex networks. Bringing all of these types and levels of analysis, and more, together into computationally and statistically intensive large-scale models is an important next step.
In fact, some preliminary disease network databases and models are currently being developed that highlight the potential for this network approach to place psychiatric diseases within broader disease networks. One can imagine an increasingly detailed biological understanding that recognizes certain cases of cooccurring diabetes, depression, and coronary artery disease as a single pathophysiological entity involving inflammation and expressing itself with organ/tissue-specific phenotypic manifestations involving the pancreas, brain, and vasculature. 7 Deeper immunogenomics could then bring a greater specificity regarding the components of the immune system that are involved in the context of each organ system. This approach moves beyond a traditional understanding of comorbidity and may facilitate the identification of novel, parsimonious, and mechanismbased treatments that attend to the tissue-specificity of pathophenotypes and their molecular context. Notably, neurological disorders likely represent a special case in their relationship with psychiatric disorders. In addition to any shared brain pathophysiological processes, the final common brain pathways that may be affected and that mediate specific functional deficits, excesses, or disruptions in perceptions, cognition, emotions, and behaviors with overlapping phenotypic expressions across neurological and psychiatric domains (eg, psychosis with anterior medial temporal lobe seizures, or anterior medial temporal lobe hyperactivity noted in schizophrenic psychosis) should be considered.
Conclusions
For the primary psychiatric disorders, the prospect of a biologically based Venn diagram with gradients along a number of clinical dimensions exists. The construction of this diagram will enable the stratification and subtyping of clinical conditions and a greater understanding of permutations of symptoms (that may cross traditional diagnostic borders, such as mood and anxiety) in individual patients. Most importantly, it will provide profiles and permit the formation of a mechanism-based understanding and treatment of a patient's illness and the factors that affect it. Achieving this goal will take time given the complexity of the objective pathophenotypes underlying psychiatric diseases and their neural network representations. However, if researchers are sufficiently patient and persistent, this approach will ultimately lead to the creation of network psychiatry and engage the clinical and research community to use it to improve diagnostic and therapeutic outcomes among psychiatric patients. This is a laudable goal that will, if pursued with persistence and commitment, lead to the realization of precision psychiatry and optimal care for patients. 
